Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

575
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
575
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Cancer Therapies02:49

Cancer Therapies

7.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

201
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
201

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal Evaluation of Sternocleidomastoid Muscle Stiffness and Self-Reported Fibrosis-Related Symptoms After Radiotherapy in Patients with Head and Neck Cancer.

Cancers·2026
Same author

Personalized Treatment of Head and Neck Cancers: Role of Functional Imaging and AI.

Cancers·2026
Same author

Pathology-informed Generative Adversarial Network Augmentation Improves Classification of Peripheral Nerve Sheath Tumors by Modeling Morphological Variability: A Pilot Investigation.

Head and neck pathology·2026
Same author

Non-Metastatic Squamous Cell Carcinoma of the Oropharynx: Primary Surgery or (Chemo)radiotherapy?

Head & neck·2026
Same author

Neoadjuvant tyrosine kinase inhibitor therapy for locally advanced, well-differentiated thyroid cancer.

The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland·2026
Same author

Strategies and successes of smoking cessation methods in head and neck cancer patients: a systematic review.

Cancer metastasis reviews·2026
Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
See all related articles

Related Experiment Video

Updated: Jul 26, 2025

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

563

Recurrent Differentiated Thyroid Cancer: The Current Treatment Options.

Andrés Coca-Pelaz1, Juan Pablo Rodrigo1, Jatin P Shah2

  • 1Department of Otolaryngology, Hospital Universitario Central de Asturias, University of Oviedo, ISPA, IUOPA, CIBERONC, 33011 Oviedo, Spain.

Cancers
|June 22, 2023
PubMed
Summary
This summary is machine-generated.

Differentiated thyroid carcinoma (DTC) recurrences, though uncommon, can be managed with surgery, radioiodine, or advanced systemic therapies like tyrosine kinase inhibitors (TKIs) for resistant cases.

Keywords:
differentiated thyroid cancerradioiodine therapysalvage surgerytargeted therapytyrosine kinase inhibitors

More Related Videos

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy
05:12

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy

Published on: May 12, 2023

3.8K
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

1.8K

Related Experiment Videos

Last Updated: Jul 26, 2025

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

563
Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy
05:12

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy

Published on: May 12, 2023

3.8K
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

1.8K

Area of Science:

  • Endocrinology
  • Oncology
  • Medical Treatment

Background:

  • Differentiated thyroid carcinomas (DTC) generally have a good prognosis.
  • Tumor recurrences occur in approximately 15% of cases, influenced by initial diagnosis and tumor biology.
  • Recurrences can manifest locally, regionally, or distantly.

Purpose of the Study:

  • To provide a comprehensive overview of current and emerging treatment strategies for differentiated thyroid carcinoma recurrences.
  • To discuss management options for cases where standard treatments like surgery or radioiodine are not feasible or effective.

Main Methods:

  • Review of current literature on differentiated thyroid carcinoma recurrence management.
  • Analysis of established treatments including surgery, radioiodine therapy, and external beam radiation.
  • Evaluation of novel systemic treatments, particularly tyrosine kinase inhibitors (TKIs).

Main Results:

  • Local and regional recurrences are often manageable with surgery and radioiodine therapy.
  • Isolated distant metastases, like bone metastases, can also respond to these standard treatments.
  • Systemic treatments, especially TKIs, show promise in improving progression-free survival for advanced or refractory cases.

Conclusions:

  • Effective management of DTC recurrences relies on timely diagnosis and tailored treatment approaches.
  • Tyrosine kinase inhibitors represent a significant advancement for patients with radioiodine-refractory or unresectable DTC recurrences.
  • Further research into systemic therapies is crucial for optimizing outcomes in recurrent DTC.